AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8419612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8419612 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone therapy
Number of subjects: 10
Study 8419612 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 10
Study 3541274 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 311
Study 3541274 — intervention group
Group type: COMPARATOR
Intervention: Vaccine
Number of subjects: 311
Study 29614245 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV-positive patients
Number of subjects: 1200
Study 29614245 — intervention group
Group type: COMPARATOR
Intervention: Influenza-positive patients
Number of subjects: 1200
Study 26527204 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliances (OAs)
Number of subjects: 9
Study 23867247 — intervention group
Group type: EXPERIMENTAL
Intervention: Xifeng Dingchan Pill (XFDCP) with Madopar for early-stage PD (n = 80)
Number of subjects: 320
Study 23867247 — intervention group
Group type: EXPERIMENTAL
Intervention: Xifeng Dingchan Pill (XFDCP) combined with Madopar and Piribedil for middle-stage PD (n = 80)
Number of subjects: 320
Study 23867247 — intervention group
Group type: COMPARATOR
Intervention: Madopar for early-stage PD (n = 80)
Number of subjects: 320
Study 23867247 — intervention group
Group type: COMPARATOR
Intervention: Madopar and Piribedil for middle-stage PD (n = 80)
Number of subjects: 320
Study 21912473 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily
Number of subjects: 1888
Study 18318267 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination co-payments
Number of subjects: 300
Study 18318267 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination subsidies
Number of subjects: 300
Study 18318267 — intervention group
Group type: EXPERIMENTAL
Intervention: Total price of influenza vaccination
Number of subjects: 300
Study 18318267 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine uptake rates
Number of subjects: 300
Study 17144453 — intervention group
Group type: EXPERIMENTAL
Intervention: Central tenotomy of levator aponeurosis
Number of subjects: 22
Study 17144453 — intervention group
Group type: EXPERIMENTAL
Intervention: Lengthening of Mullers' muscle combined with levator muscle
Number of subjects: 22
Study 12743150 — intervention group
Group type: EXPERIMENTAL
Intervention: letrozole
Number of subjects: 562
Study 12743150 — intervention group
Group type: COMPARATOR
Intervention: tamoxifen
Number of subjects: 562
Study 10764480 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg nitroglycerin
Number of subjects: 62
Study 10764480 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg nitroglycerin
Number of subjects: 62
Study 10764480 — intervention group
Group type: COMPARATOR
Intervention: Physiologic sodium chloride solution (placebo)
Number of subjects: 62
Study 9184388 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant hirudin (HBW 023)
Number of subjects: 155
Study 9184388 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sodium heparin
Number of subjects: 155
Study 1530173 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine (112.5 mg)
Number of subjects: 44
Study 1530173 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine (112.5 mg)
Number of subjects: 44
Study 3652468 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2 supplementation (1000 IU)
Number of subjects: 39
Study 3652468 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2 supplementation (3000 IU)
Number of subjects: 39
Study 3652468 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 39
Study 28104042 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit of medical records
Number of subjects: 200
Study 28104042 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit of discharge summaries
Number of subjects: 200
Study 28104042 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence of discharge summary distribution
Number of subjects: 200
Study 27333004 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) using resorbable minimembrane and particulate xenograft (DBBM)
Number of subjects: 20
Study 27333004 — intervention group
Group type: EXPERIMENTAL
Intervention: Inductive periodontal regeneration (IPR) using enamel matrix derivatives and DBBM
Number of subjects: 20
Study 27333004 — intervention group
Group type: COMPARATOR
Intervention: GTR
Number of subjects: 20
Study 27333004 — intervention group
Group type: COMPARATOR
Intervention: IPR
Number of subjects: 20
Study 24095004 — intervention group
Group type: EXPERIMENTAL
Intervention: Semirigid (small) titanium plates
Number of subjects: 127
Study 24095004 — intervention group
Group type: COMPARATOR
Intervention: Rigid (large) titanium plates
Number of subjects: 127
Study 23248825 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual patient safety vignettes
Number of subjects: 24
Study 23248825 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods of instruction (lecture and written case studies)
Number of subjects: 24
Study 20552291 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood ALL survivors
Number of subjects: 21
Study 20552291 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 21
Study 18544618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment for 16 weeks
Number of subjects: 24
Study 18544618 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched control subjects)
Number of subjects: 24
Study 20921315 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline (100 mg loading dose followed by 50 mg every 12 hours)
Number of subjects: 0
Study 15730366 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension‐free Vaginal Tape (TVT)
Number of subjects: 195
Study 15730366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal Sling (IVS)
Number of subjects: 195
Study 15730366 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic Arc Sling (SPARC)
Number of subjects: 195
Study 12049012 — intervention group
Group type: COMPARATOR
Intervention: Conventional absorbable subcutaneous Polyglactin 910 (VICRYL, ETHICON) and non absorbable cutaneous Monofilament Nylon (ETHILON, ETHICON) stitches
Number of subjects: 50
Study 12049012 — intervention group
Group type: EXPERIMENTAL
Intervention: Running subcutaneous and intradermic irradiated Polyglactin 910/370 (VICRYL‐Rapide, ETHICON) sutures
Number of subjects: 50
Study 12049012 — intervention group
Group type: EXPERIMENTAL
Intervention: VICRYL‐Rapide
Number of subjects: 50
Study 9623020 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone/sulbactam (25 mg/kg/day) + co-trimoxazole (8 mg/kg/day)
Number of subjects: 84
Study 9623020 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (100 mg/kg/day) + co-trimoxazole (8 mg/kg/day)
Number of subjects: 84
Study 9623020 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 84
Study 7945744 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (0.01 mg/kg SC)
Number of subjects: 12
Study 7945744 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-212 (20 mg PO)
Number of subjects: 12
Study 7945744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3111514 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg orally four times daily for 4 days
Number of subjects: 15
Study 3111514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg orally twice daily for 4 days
Number of subjects: 15
Study 3111514 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide administered alone
Number of subjects: 15
Study 3111514 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide with cimetidine
Number of subjects: 15
Study 3111514 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide with ranitidine
Number of subjects: 15
Study 31425385 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCONLY contraction at 110% 1RM
Number of subjects: 32
Study 31425385 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCONLY contraction at 130% 1RM
Number of subjects: 32
Study 31425385 — intervention group
Group type: COMPARATOR
Intervention: CONONLY contraction at 90% 1RM
Number of subjects: 32
Study 31425385 — intervention group
Group type: COMPARATOR
Intervention: ECCONLY contraction at 90% 1RM
Number of subjects: 32
Study 29933369 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 413
Study 29933369 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity sustained exercise (EX)
Number of subjects: 413
Study 29933369 — intervention group
Group type: COMPARATOR
Intervention: Observational waitlist control
Number of subjects: 413
Study 27523814 — intervention group
Group type: EXPERIMENTAL
Intervention: External application of ligustrazine combined with holistic nursing
Number of subjects: 32
Study 27523814 — intervention group
Group type: COMPARATOR
Intervention: Compound clotrimazole cream (Control)
Number of subjects: 32
Study 23869585 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine
Number of subjects: 150
Study 23869585 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 150
Study 23869585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 23027184 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive step training with preparatory visual cues
Number of subjects: 28
Study 23027184 — intervention group
Group type: COMPARATOR
Intervention: Lower limb strength training
Number of subjects: 28
Study 20537645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic leg ergometry exercise for 30 min during each hemodialysis session for 8 weeks
Number of subjects: 71
Study 20537645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic leg ergometry exercise
Number of subjects: 71
Study 20537645 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary subjects in the experimental group
Number of subjects: 71
Study 20537645 — intervention group
Group type: COMPARATOR
Intervention: Sedentary subjects in the control group
Number of subjects: 71
Study 20537645 — intervention group
Group type: EXPERIMENTAL
Intervention: Active subjects in the experimental group
Number of subjects: 71
Study 19080629 — intervention group
Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao
Number of subjects: 40
Study 19080629 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 40
Study 15705011 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (75 to 225 mg/day)
Number of subjects: 271
Study 15705011 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER
Number of subjects: 271
Study 15705011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 12869713 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of restricted leukoaraiosis (LA)
Number of subjects: 596
Study 12869713 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of widespread leukoaraiosis (LA)
Number of subjects: 596
Study 12869713 — intervention group
Group type: EXPERIMENTAL
Intervention: Occurrence of strokes in patients who developed LA
Number of subjects: 596
Study 12869713 — intervention group
Group type: EXPERIMENTAL
Intervention: Small deep infarcts in patients who developed LA
Number of subjects: 596
Study 12869713 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression from restricted to widespread LA
Number of subjects: 596
Study 10680105 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐tubocurarine 0.05 mg/kg
Number of subjects: 80
Study 10680105 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium 0.06 mg/kg
Number of subjects: 80
Study 10680105 — intervention group
Group type: EXPERIMENTAL
Intervention: cisatracurium 0.01 mg/kg
Number of subjects: 80
Study 10680105 — intervention group
Group type: COMPARATOR
Intervention: placebo (saline)
Number of subjects: 80
Study 10680105 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study 8983613 — intervention group
Group type: EXPERIMENTAL
Intervention: mannitol 0.3 g/kg
Number of subjects: 28
Study 8983613 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 28
Study 2015475 — intervention group
Group type: EXPERIMENTAL
Intervention: Light reflection rheography
Number of subjects: 124
Study 7199328 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (Ro 21-3981, Dormicum)
Number of subjects: 0
Study 7199328 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study 30445999 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle intervention program
Number of subjects: 240
Study 30445999 — intervention group
Group type: COMPARATOR
Intervention: Letrozole (oral fertility medication)
Number of subjects: 240
Study 30445999 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol (supplement)
Number of subjects: 240
Study 30445999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 27902622 — intervention group
Group type: EXPERIMENTAL
Intervention: Penetration acupuncture treatment on head combined with conventional treatment (treatment group [TG])
Number of subjects: 82
Study 27902622 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment only (control group [CG])
Number of subjects: 82
Study 23295099 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading with a fixed temporary bridge
Number of subjects: 50
Study 23295099 — intervention group
Group type: COMPARATOR
Intervention: Control group (unloaded for 3 months)
Number of subjects: 50
Study 22974108 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute brief interactive session combining structured advice and motivational interviewing techniques delivered by the school learning mentor (level 1 condition, n=2 schools)
Number of subjects: 7
Study 22974108 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minute session involving family members delivered by the school learning mentor (level 2 condition, n=3 schools)
Number of subjects: 7
Study 22974108 — intervention group
Group type: COMPARATOR
Intervention: Provision of an advice leaflet (control condition, n=2 schools)
Number of subjects: 7
Study 22974108 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 6 and 12 months for all participants
Number of subjects: 7
Study 22974108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten-question Alcohol-Use Disorders Identification Test as a secondary outcome measure
Number of subjects: 7
Study 22974108 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-Y and a modified short service use questionnaire for health and social resource costs
Number of subjects: 7
Study 22974108 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-day timeline follow back questionnaire at 12-month follow-up
Number of subjects: 7
Study 22974108 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative evaluation with young people, school staff, learning mentors, and parents
Number of subjects: 7
Study 20353458 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 IU recombinant FSH
Number of subjects: 131
Study 20353458 — intervention group
Group type: COMPARATOR
Intervention: 225 IU recombinant FSH
Number of subjects: 131
Study 18852875 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1 g twice daily)
Number of subjects: 100
Study 18852875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 16154855 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 3-hour fast infusions of arsenic trioxide (As2O3)
Number of subjects: 0
Study 16154855 — intervention group
Group type: COMPARATOR
Intervention: Daily slow, continuous infusions of arsenic trioxide (As2O3)
Number of subjects: 0
Study 15320641 — intervention group
Group type: EXPERIMENTAL
Intervention: Lift Day (LD)
Number of subjects: 18
Study 15320641 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study 10655437 — intervention group
Group type: EXPERIMENTAL
Intervention: New guidelines for tumor response evaluation
Number of subjects: 0
Study 10655437 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined assessment of target and nontarget lesions
Number of subjects: 0
Study 9170398 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting nifedipine 30 mg/d
Number of subjects: 1115
Study 9170398 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting diltiazem 90 mg/d
Number of subjects: 1115
Study 9170398 — intervention group
Group type: COMPARATOR
Intervention: No calcium antagonist
Number of subjects: 1115
Study 1487549 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting state
Number of subjects: 11
Study 1487549 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized breakfast
Number of subjects: 11
Study 1487549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g
Number of subjects: 11
Study 2984710 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana cigarette containing 100, 200, or 250 micrograms/kg THC
Number of subjects: 0
Study 31356878 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP7962 (100 mg BID)
Number of subjects: 215
Study 31356878 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen (500 mg BID)
Number of subjects: 215
Study 31356878 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 215
Study 30146144 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Cognitive-Behavioral Therapy (CBT)
Number of subjects: 69
Study 30146144 — intervention group
Group type: EXPERIMENTAL
Intervention: Less-Structured Cognitive-Behavioral Therapy (CBT)
Number of subjects: 69
Study 26429567 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical debridement (MD)
Number of subjects: 60
Study 26429567 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency chondroplasty (RF)
Number of subjects: 60
Study 26429567 — intervention group
Group type: EXPERIMENTAL
Intervention: KOOS assessment
Number of subjects: 60
Study 26429567 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint space width
Number of subjects: 60
Study 24743428 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 0
Study 24743428 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers
Number of subjects: 0
Study 22775128 — intervention group
Group type: EXPERIMENTAL
Intervention: Intergroup anxiety
Number of subjects: 0
Study 20472865 — intervention group
Group type: EXPERIMENTAL
Intervention: Agar nasal catheter
Number of subjects: 26
Study 20472865 — intervention group
Group type: COMPARATOR
Intervention: Continuously perfusing nasal catheter
Number of subjects: 26
Study 19045975 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus contingency management
Number of subjects: 1687
Study 19045975 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus motivational enhancement
Number of subjects: 1687
Study 19045975 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1687
Study 15886380 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/d of DG-031
Number of subjects: 191
Study 15886380 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/d of DG-031
Number of subjects: 191
Study 15886380 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg/d of DG-031
Number of subjects: 191
Study 15886380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 15886380 — intervention group
Group type: EXPERIMENTAL
Intervention: DG-031 (higher doses)
Number of subjects: 191
Study 12652180 — intervention group
Group type: EXPERIMENTAL
Intervention: RV + MCV -> Can
Number of subjects: 10
Study 12652180 — intervention group
Group type: COMPARATOR
Intervention: RV -> SVC + Can
Number of subjects: 10
Study 9792571 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (5, 10, and 20 mg/d)
Number of subjects: 12
Study 9792571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9792571 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (1, 2, and 4 mg/d)
Number of subjects: 12
Study 8704419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nourishing the Liver treatment
Number of subjects: 0
Study 8704419 — intervention group
Group type: COMPARATOR
Intervention: Invigorating the Spleen control
Number of subjects: 0
Study 2533509 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-session, 10-week intervention focused on enhancing perceived control
Number of subjects: 0
Study 2533509 — intervention group
Group type: COMPARATOR
Intervention: Placebo-contact group
Number of subjects: 0
Study 2533509 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 0
Study 904879 — intervention group
Group type: EXPERIMENTAL
Intervention: Iridocapsular lenses
Number of subjects: 200
Study 904879 — intervention group
Group type: COMPARATOR
Intervention: Iris-clip lenses
Number of subjects: 200
Study 29168127 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.70 mg/kg DAA-I
Number of subjects: 3
Study 29168127 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.08 mg/kg DAA-I
Number of subjects: 3
Study 29168127 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg DAA-I
Number of subjects: 3
Study 26610858 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT plus Docetaxel (D)
Number of subjects: 385
Study 26610858 — intervention group
Group type: COMPARATOR
Intervention: ADT alone
Number of subjects: 385
Study 24045586 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclizine 12.5 mg
Number of subjects: 24
Study 24045586 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclizine 25 mg
Number of subjects: 24
Study 24045586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24045586 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclizine (both doses)
Number of subjects: 24
Study 22972857 — intervention group
Group type: EXPERIMENTAL
Intervention: Composites (bisphenol‐A‐diglycidyl‐dimethacrylate composite for permanent teeth, urethane‐dimethacrylate compomer for primary teeth)
Number of subjects: 474
Study 22972857 — intervention group
Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 474
Study 22972857 — intervention group
Group type: EXPERIMENTAL
Intervention: Composites (for girls)
Number of subjects: 474
Study 22972857 — intervention group
Group type: COMPARATOR
Intervention: Amalgam (for girls)
Number of subjects: 474
Study 18332760 — intervention group
Group type: EXPERIMENTAL
Intervention: Round bar attachment
Number of subjects: 26